Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: Three-year follow-up from the resilient randomized trial

John R. Laird, Barry T. Katzen, Dierk Scheinert, Johannes Lammer, Jeffrey Carpenter, Maurice Buchbinder, Rajesh Dave, Gary Ansel, Alexandra Lansky, Ecaterina Cristea, Tyrone J. Collins, Jeffrey Goldstein, Annie Y. Cao, Michael R. Jaff

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Purpose: To evaluate longer outcomes of primary nitinol stenting for the treatment of femoropopliteal lesions up to 15 cm long after these stents were found to have superior short-term patency vs. balloon angioplasty. Methods: Two hundred and six patients (143 men; mean age 67 years) with intermittent claudication due to superficial femoral and proximal popliteal artery lesions were randomized (2:1) to treatment with nitinol stents or balloon angioplasty at 24 US and European centers and followed for 3 years. In that time, 15 patients died, 20 withdrew consent, and 10 were lost to follow-up, leaving 161 (78.2%) patients for 36-month assessment. Results: The 12-month freedom from target lesion revascularization (TLR) was 87.3% for the stent group vs. 45.2% for the angioplasty group (p<0.0001). At 3 years, there was no difference in survival (90.0% vs. 91.7%, p50.71) or major adverse events (75.2% vs. 75.2%, p=0.98) between the stent and angioplasty groups. Duplex ultrasound was not mandated after the first year, so stent patency could not be ascertained beyond 1 year, but freedom from TLR at 3 years was significantly better in the stent group (75.5% vs. 41.8%, p<0.0001), as was clinical success (63.2% vs. 17.9%, p<0.0001). At 18 months, a 4.1% (12/291) stent fracture rate was documented. Conclusion: In this multicenter trial, primary implantation of a nitinol stent for moderatelength lesions in the femoropopliteal segment of patients with claudication was associated with better long-term results vs. balloon angioplasty alone.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Endovascular Therapy
Volume19
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Popliteal Artery
Balloon Angioplasty
Thigh
Stents
Angioplasty
Intermittent Claudication
nitinol
Lost to Follow-Up
Multicenter Studies
Survival
Therapeutics

Keywords

  • Balloon angioplasty
  • Claudication
  • Femoropopliteal segment
  • Outcome analysis
  • Peripheral vascular disease
  • Popliteal artery
  • Quality of life outcome
  • Stenosis
  • Stents
  • Superficial femoral artery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication : Three-year follow-up from the resilient randomized trial. / Laird, John R.; Katzen, Barry T.; Scheinert, Dierk; Lammer, Johannes; Carpenter, Jeffrey; Buchbinder, Maurice; Dave, Rajesh; Ansel, Gary; Lansky, Alexandra; Cristea, Ecaterina; Collins, Tyrone J.; Goldstein, Jeffrey; Cao, Annie Y.; Jaff, Michael R.

In: Journal of Endovascular Therapy, Vol. 19, No. 1, 2012, p. 1-9.

Research output: Contribution to journalArticle

Laird, JR, Katzen, BT, Scheinert, D, Lammer, J, Carpenter, J, Buchbinder, M, Dave, R, Ansel, G, Lansky, A, Cristea, E, Collins, TJ, Goldstein, J, Cao, AY & Jaff, MR 2012, 'Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: Three-year follow-up from the resilient randomized trial', Journal of Endovascular Therapy, vol. 19, no. 1, pp. 1-9. https://doi.org/10.1583/11-3627.1
Laird, John R. ; Katzen, Barry T. ; Scheinert, Dierk ; Lammer, Johannes ; Carpenter, Jeffrey ; Buchbinder, Maurice ; Dave, Rajesh ; Ansel, Gary ; Lansky, Alexandra ; Cristea, Ecaterina ; Collins, Tyrone J. ; Goldstein, Jeffrey ; Cao, Annie Y. ; Jaff, Michael R. / Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication : Three-year follow-up from the resilient randomized trial. In: Journal of Endovascular Therapy. 2012 ; Vol. 19, No. 1. pp. 1-9.
@article{9e37bccd6c074b0a9d759e3f308740f9,
title = "Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: Three-year follow-up from the resilient randomized trial",
abstract = "Purpose: To evaluate longer outcomes of primary nitinol stenting for the treatment of femoropopliteal lesions up to 15 cm long after these stents were found to have superior short-term patency vs. balloon angioplasty. Methods: Two hundred and six patients (143 men; mean age 67 years) with intermittent claudication due to superficial femoral and proximal popliteal artery lesions were randomized (2:1) to treatment with nitinol stents or balloon angioplasty at 24 US and European centers and followed for 3 years. In that time, 15 patients died, 20 withdrew consent, and 10 were lost to follow-up, leaving 161 (78.2{\%}) patients for 36-month assessment. Results: The 12-month freedom from target lesion revascularization (TLR) was 87.3{\%} for the stent group vs. 45.2{\%} for the angioplasty group (p<0.0001). At 3 years, there was no difference in survival (90.0{\%} vs. 91.7{\%}, p50.71) or major adverse events (75.2{\%} vs. 75.2{\%}, p=0.98) between the stent and angioplasty groups. Duplex ultrasound was not mandated after the first year, so stent patency could not be ascertained beyond 1 year, but freedom from TLR at 3 years was significantly better in the stent group (75.5{\%} vs. 41.8{\%}, p<0.0001), as was clinical success (63.2{\%} vs. 17.9{\%}, p<0.0001). At 18 months, a 4.1{\%} (12/291) stent fracture rate was documented. Conclusion: In this multicenter trial, primary implantation of a nitinol stent for moderatelength lesions in the femoropopliteal segment of patients with claudication was associated with better long-term results vs. balloon angioplasty alone.",
keywords = "Balloon angioplasty, Claudication, Femoropopliteal segment, Outcome analysis, Peripheral vascular disease, Popliteal artery, Quality of life outcome, Stenosis, Stents, Superficial femoral artery",
author = "Laird, {John R.} and Katzen, {Barry T.} and Dierk Scheinert and Johannes Lammer and Jeffrey Carpenter and Maurice Buchbinder and Rajesh Dave and Gary Ansel and Alexandra Lansky and Ecaterina Cristea and Collins, {Tyrone J.} and Jeffrey Goldstein and Cao, {Annie Y.} and Jaff, {Michael R.}",
year = "2012",
doi = "10.1583/11-3627.1",
language = "English (US)",
volume = "19",
pages = "1--9",
journal = "Journal of Endovascular Therapy",
issn = "1526-6028",
publisher = "International Society of Endovascular Specialists",
number = "1",

}

TY - JOUR

T1 - Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication

T2 - Three-year follow-up from the resilient randomized trial

AU - Laird, John R.

AU - Katzen, Barry T.

AU - Scheinert, Dierk

AU - Lammer, Johannes

AU - Carpenter, Jeffrey

AU - Buchbinder, Maurice

AU - Dave, Rajesh

AU - Ansel, Gary

AU - Lansky, Alexandra

AU - Cristea, Ecaterina

AU - Collins, Tyrone J.

AU - Goldstein, Jeffrey

AU - Cao, Annie Y.

AU - Jaff, Michael R.

PY - 2012

Y1 - 2012

N2 - Purpose: To evaluate longer outcomes of primary nitinol stenting for the treatment of femoropopliteal lesions up to 15 cm long after these stents were found to have superior short-term patency vs. balloon angioplasty. Methods: Two hundred and six patients (143 men; mean age 67 years) with intermittent claudication due to superficial femoral and proximal popliteal artery lesions were randomized (2:1) to treatment with nitinol stents or balloon angioplasty at 24 US and European centers and followed for 3 years. In that time, 15 patients died, 20 withdrew consent, and 10 were lost to follow-up, leaving 161 (78.2%) patients for 36-month assessment. Results: The 12-month freedom from target lesion revascularization (TLR) was 87.3% for the stent group vs. 45.2% for the angioplasty group (p<0.0001). At 3 years, there was no difference in survival (90.0% vs. 91.7%, p50.71) or major adverse events (75.2% vs. 75.2%, p=0.98) between the stent and angioplasty groups. Duplex ultrasound was not mandated after the first year, so stent patency could not be ascertained beyond 1 year, but freedom from TLR at 3 years was significantly better in the stent group (75.5% vs. 41.8%, p<0.0001), as was clinical success (63.2% vs. 17.9%, p<0.0001). At 18 months, a 4.1% (12/291) stent fracture rate was documented. Conclusion: In this multicenter trial, primary implantation of a nitinol stent for moderatelength lesions in the femoropopliteal segment of patients with claudication was associated with better long-term results vs. balloon angioplasty alone.

AB - Purpose: To evaluate longer outcomes of primary nitinol stenting for the treatment of femoropopliteal lesions up to 15 cm long after these stents were found to have superior short-term patency vs. balloon angioplasty. Methods: Two hundred and six patients (143 men; mean age 67 years) with intermittent claudication due to superficial femoral and proximal popliteal artery lesions were randomized (2:1) to treatment with nitinol stents or balloon angioplasty at 24 US and European centers and followed for 3 years. In that time, 15 patients died, 20 withdrew consent, and 10 were lost to follow-up, leaving 161 (78.2%) patients for 36-month assessment. Results: The 12-month freedom from target lesion revascularization (TLR) was 87.3% for the stent group vs. 45.2% for the angioplasty group (p<0.0001). At 3 years, there was no difference in survival (90.0% vs. 91.7%, p50.71) or major adverse events (75.2% vs. 75.2%, p=0.98) between the stent and angioplasty groups. Duplex ultrasound was not mandated after the first year, so stent patency could not be ascertained beyond 1 year, but freedom from TLR at 3 years was significantly better in the stent group (75.5% vs. 41.8%, p<0.0001), as was clinical success (63.2% vs. 17.9%, p<0.0001). At 18 months, a 4.1% (12/291) stent fracture rate was documented. Conclusion: In this multicenter trial, primary implantation of a nitinol stent for moderatelength lesions in the femoropopliteal segment of patients with claudication was associated with better long-term results vs. balloon angioplasty alone.

KW - Balloon angioplasty

KW - Claudication

KW - Femoropopliteal segment

KW - Outcome analysis

KW - Peripheral vascular disease

KW - Popliteal artery

KW - Quality of life outcome

KW - Stenosis

KW - Stents

KW - Superficial femoral artery

UR - http://www.scopus.com/inward/record.url?scp=84857133568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857133568&partnerID=8YFLogxK

U2 - 10.1583/11-3627.1

DO - 10.1583/11-3627.1

M3 - Article

C2 - 22313193

AN - SCOPUS:84857133568

VL - 19

SP - 1

EP - 9

JO - Journal of Endovascular Therapy

JF - Journal of Endovascular Therapy

SN - 1526-6028

IS - 1

ER -